Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 26

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
’s articles of incorporation and bylaws, as amended and in
effect as of the date hereof, and provides for contribution rights in the event indemnification is unavailable.

17

Item 2. Management’s Discussion and Analysis
of Financial Condition and Results of Operations

Forward-Looking Statements

This Form 10-Q contains certain
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements
contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting
the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,”
“estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. These
statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety
of factors, many of which are not within our control. These factors include but are not limited to economic conditions generally and in
the industries in which we may participate; competition within our chosen industry, including competition from much larger competitors;
technological advances and failure to successfully develop business relationships.

Description of Business

Overview

Our objective is to
develop and commercialize our product candidates to treat diseases where the innate immune system is dysfunctional causing or
contributing to the patient’s disease. Innate immune dysfunction can occur for a variety of reasons including genetics,
lifestyle, and other factors. However, age plays a significant role in the development of immune dysfunction. Innate immune
dysfunction can be seen in cancer where Natural Killer (“NK”) cells are impaired and facilitate a tumor’s evasion
of the immune system and subsequent disease progression. Chronic inflammation is implicated in various diseases, where it impairs
the innate immune system. Our primary focus continues to be treatment of cancer with INKmune, treatment of Alzheimer’s Disease
(“AD”) with XPro1595 and treatment of receswsive dystrophic epidermolysis bullosa (RDEB) with CORDStrom, a proprietary,
pooled, human umbilical cord mesenchymal stromal cell platform. RDEB is a pediatric orphan disease caused by mutations in the COL7A1
gene which results in highly debilitating skin blistering, dysphagia and failure to thrive with chronic wound problems that often
result in fatal squamous cell carcinoma.

XPro for AD has completed
Phase I and